Dr. Ali Al-Ghamrawy: Strategic partnership enhances Egypt’s attractiveness for pharmaceutical investment and reinforces its position as a regional pharmaceutical manufacturing hub

Adrien Delamare Deboutteville: A continuous commitment to supporting the healthcare system and providing innovative medications and vaccines

Philip D. Haas: New investment to support pharmaceutical manufacturing and expand into African and Middle Eastern markets

....

Dr. Ali Al-Ghamrawy, Chairman of the Egyptian Drug Authority, witnessed the signing of a strategic industrial partnership between Sanofi Egypt and East Pharma for Pharmaceuticals. Under the agreement, ownership of Sanofi’s manufacturing factory in Cairo will be transferred to East Pharma. This step aims to support the long-term sustainability of pharmaceutical manufacturing in Egypt, strengthen local manufacturing capabilities, and open new horizons for investment and expansion into regional and international markets.

This partnership reflects the growing attractiveness of the Egyptian market for international pharmaceutical investment and confidence in the industrial capabilities and human resources of Egypt’s pharmaceutical sector. It also supports the state’s efforts to establish Egypt as a regional pharmaceutical manufacturing hub and strengthen pharmaceutical products security in line with Egypt Vision 2030.

In this context, Dr. Ali Al-Ghamrawy affirmed that this strategic agreement reflects Egypt’s growing attractiveness for pharmaceutical investment and the establishment of regional pharmaceutical manufacturing hubs. He noted that East Pharma’s investment in Sanofi’s Cairo factory demonstrates confidence in Egypt’s industrial capabilities and a shared vision for advancing the pharmaceutical sector.

He also welcomed East Pharma as a new investor in the Egyptian market, expressing his aspiration for the partnership to contribute to strengthening pharmaceutical products security, fostering innovation, and enhancing the competitiveness of Egypt’s pharmaceutical sector.

Adrien Delamare Deboutteville, Head of Pharma for Africa and Egypt at Sanofi, reaffirmed the company’s long-term commitment to the Egyptian market. He noted that Sanofi has been operating in Egypt for more than 60 years and that its role extends beyond providing pharmaceutical products to collaborating with Egyptian authorities to address healthcare challenges through strategic partnerships, continuous medical training, the use of artificial intelligence, and the advancement of digital innovation.

Looking ahead, Sanofi Egypt continues to strengthen its partnerships with various stakeholders across the healthcare system to support access to innovative products and vaccines and develop solutions and programs that help meet the needs of Egyptian patients.

For his part, Philip D. Haas, Chairman of the Board of East Pharma for Pharmaceuticals, expressed his pride in investing in Egypt and building on the well-established industrial foundations of Sanofi’s Cairo factory while benefiting from the expertise and capabilities of its workforce. He emphasized that the investment would support the continuation of the factory’s operations and enhance its production capabilities, while providing a platform for expanding manufacturing and exports to African and Middle Eastern markets. This reflects the company’s long-term commitment to Egypt and its confidence in the country’s pharmaceutical sector.

East Pharma has a comprehensive pharmaceutical portfolio covering various stages of the production chain, from active pharmaceutical ingredients to finished pharmaceutical products. Its therapeutic portfolio also spans several medical fields, including neurology, oncology, ophthalmology, respiratory diseases, dermatology, cardiology, and immunology.

This partnership comes as part of the Egyptian Drug Authority’s efforts to support the sustainability of pharmaceutical production in Egypt, strengthen industrial capabilities, and expand manufacturing and export opportunities across African and Middle Eastern markets, thereby enhancing the competitiveness of Egypt’s pharmaceutical industry and its capacity to meet the needs of both the local market and regional markets.